Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 months
Open Access
- 20 June 2024
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 70 (3) , 333-345
Abstract
Introduction/Aims: In amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations (SOD1‐ALS), tofersen received accelerated approval in the United States and is available via expanded access programs (EAP) outside the United States. This multicenter study investigates clinical and patient‐reported outcomes (PRO) and serum neurofilament light chain (sNfL) during tofersen treatment in an EAP in Germany.Methods: Sixteen SOD1‐ALS patients receiving tofersen for at least 6 months were analyzed. The ALS progression rate (ALS‐PR), as measured by the monthly change of the ALS functional rating scale—revised (ALSFRS‐R), slow vital capacity (SVC), and sNfL were investigated. PRO included the Measure Yourself Medical Outcome Profile (MYMOP2), Treatment Satisfaction Questionnaire for Medication (TSQM‐9), and Net Promoter Score (NPS).Results: Mean tofersen treatment was 11 months (6–18 months). ALS‐PR showed a mean change of −0.2 (range 0 to −1.1) and relative reduction by 25%. Seven patients demonstrated increased ALSFRS‐R. SVC was stable (mean 88%, range −15% to +28%). sNfL decreased in all patients except one heterozygous D91A‐SOD1 mutation carrier (mean change of sNfL −58%, range −91 to +27%, p < .01). MYMOP2 indicated improved symptom severity (n = 10) or yet perception of partial response (n = 6). TSQM‐9 showed high global treatment satisfaction (mean 83, SD 16) although the convenience of drug administration was modest (mean 50, SD 27). NPS revealed a very high recommendation rate for tofersen (NPS +80).Discussion: Data from this EAP supported the clinical and sNfL response to tofersen in SOD1‐ALS. PRO suggested a favorable patient perception of tofersen treatment in clinical practice.Keywords
This publication has 39 references indexed in Scilit:
- Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access programeClinicalMedicine, 2024
- Quality‐of‐life assessment instruments used across ALS clinicsMuscle & Nerve, 2023
- Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practiceMuscle & Nerve, 2023
- Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): a national, cross-sectional studyeClinicalMedicine, 2022
- Longitudinal comparison of the self‐entry Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised (ALSFRS‐RSE) and Rasch‐Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosisMuscle & Nerve, 2022
- Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyNeurotherapeutics, 2022
- Individualized health-related quality of life instrument Measure Yourself Medical Outcome Profile (MYMOP) and its adaptations: a critical appraisalQuality of Life Research, 2018
- Seeking the Patient's Perspective: A Qualitative Assessment of EuroQol, COOP-WONCA Charts and MYMOPQuality of Life Research, 2004
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory functionJournal of the Neurological Sciences, 1999
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993